Hansa Medical to Host Conference Call to Provide Second Quarter 2017 Business Update
On 20 July 2017, at 08:00AM CEST, Hansa Medical will publish its report for the second quarter of 2017. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CEST.
The event will be hosted by Hansa Medical’s CEO and President, Göran Arvidson, and the presentation will be held in English.
Slides used in the presentation will be live on the company’s website during the call under Events & Webcast and will also be made available after the call. To participate in the telephone conference, please call:
SE: +46 (0) 856 642 690
UK: +44 (0) 2030 089 801
US: +1 855 753 2235
A link to audio cast can be found on the Hansa Medical website under Events & Webcasts or here: https://tv.streamfabriken.com/hansa-medical-q2-2017
Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobile: +46707175477
E-mail: emanuel.bjorne@hansamedical.com
Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960
Lars Wahlström
Mobile: +46 73 434 0771
FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibodydegrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.
Tags: